NEW YORK (GenomeWeb News) – Response Genetics has signed a deal with Roche Diagnostics to support the development of a cancer assay.

The Los Angeles-based firm said today that it had licensed to Roche non-exclusive rights to use its PCR analysis technology to assess human epidermal growth factor type 2 gene expression. A test that can accurately measure HER2 expression could assist physicians with treatment decisions for patients with certain cancers in tissues such as breast.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Vivek Murthy is no longer the surgeon general of the US, the Associated Press reports.

People around the globe took to the streets to support science — some with signs.

Parents who learn of their increased genetic risk of disease also contend with telling their children about theirs, the New York Times writes.

In PLOS this week: loci linked to body mass index measurements, long non-coding RNA expression and urothelial carcinoma prognosis, and more.